Proteins and Peptides

10 Jul 2018 Filament BioSolutions Announces Collaboration with Ajinomoto for the Development of FB-2710 for Radiation-Induced Oral Mucositis
10 Jul 2018 Codexis Doses First Subjects in Phase 1a Trial of CDX-6114
06 Jul 2018 Herantis Pharma initiates non-invasive CDNF development program, announces licensing agreement with University of Helsinki
04 Jul 2018 FDA Approves XEOMIN® (incobotulinumtoxinA) for Adult Patients with Sialorrhea
03 Jul 2018 CHMP recommends EU marketing authorization for Veyvondi® [vonicog alfa, recombinant von Willebrand factor] for adults with von willebrand disease
02 Jul 2018 VarmX Raises € 12.5 Million to Develop Modified Blood Coagulation Factor X for Treating Severe Bleeding in Patients Using Anti-Coagulants
01 Jul 2018 Ultragenyx Announces Positive CHMP Opinion for Mepsevii™ (vestronidase alfa) For the Treatment of Mucopolysaccharidosis VII
29 Jun 2018 Spectrum Pharmaceuticals Presents ADVANCE Phase 3 ROLONTIS® (eflapegrastim) Data at MASCC 2018 and Announces the Phase 3 RECOVER Study Met the Primary Endpoint
29 Jun 2018 AzurRx BioPharma Announces Successful Phase IIa Trial of MS1819-SD in Exocrine Pancreatic Insufficiency
28 Jun 2018 Oral semaglutide shows superior reductions in HbA1c and weight compared to sitagliptin in the long-term safety and efficacy trial, PIONEER 3
27 Jun 2018 Enteris BioPharma Announces Positive Results from Expanded Phase 2a Clinical Trial of Ovarest® (oral leuprolide tablet) for Endometriosis
27 Jun 2018 Apellis Pharmaceuticals Announces First Patient Enrolled in Phase 3 APL-2 Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Soliris
26 Jun 2018 Cerenis Therapeutics: First results of TARGET PHASE II study demonstrate the ability of CER-001, an HDL mimetic, to target tumor in patients with esophageal cancer
26 Jun 2018 Xeris Pharmaceuticals Announces Positive Phase 3 Clinical Trial Data on Its Investigational Ready-to-Use Glucagon Rescue Pen
26 Jun 2018 Stemline Therapeutics Announces Completion of Rolling BLA Submission for ELZONRIS™ (tagraxofusp; SL-401) for the Treatment of BPDCN
25 Jun 2018 Sophiris Bio Reports Top-Line Interim Safety and Biopsy Findings For its Phase 2b Clinical Trial of Topsalysin in Localized Prostate Cancer
24 Jun 2018 Oral semaglutide demonstrated significant reduction in blood sugar vs placebo in PIONEER 1 trial
22 Jun 2018 Revance Doses First Patient in ASPEN Phase 3 Clinical Program of RT002 Injectable for the Treatment of Cervical Dystonia
21 Jun 2018 Oral semaglutide shows statistically significantly greater reductions in HbA1c and weight compared to Victoza® and sitagliptin in the PIONEER 4 and 7 trials
19 Jun 2018 Leading BioSciences Reports Positive Interim Results from Phase 2 Trial of LB1148 in Patients Undergoing Major Surgery
19 Jun 2018 Allena Pharmaceuticals Completes Animal Proof-of-Concept Study for ALLN-346, Lead Product Candidate for Hyperuricemia in the Setting of Advanced Chronic Kidney Disease
19 Jun 2018 Clover Biopharmaceuticals Doses First Patient in Australia in Phase I Study of SCB-313 for Malignant Ascites
19 Jun 2018 Catalyst Biosciences Provides Update on CB 2679d/ISU304 Factor IX Clinical Program in Hemophilia B
19 Jun 2018 Stemline Therapeutics Announces Positive Clinical Data from ELZONRISTM (tagraxofusp; SL-401) Trials in BPDCN, CMML and MF Delivered at the EHA Congress
15 Jun 2018 Selecta Biosciences Presents Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at EULAR 2018

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up